Background-Several recent randomized trials comparing everolimus-eluting stent (EES) and sirolimus-eluting stent (SES) reported similar outcomes. However, only 1 trial was powered for a clinical end point, and no trial was powered for evaluating target-lesion revascularization. Methods and Results-Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial is a prospective multicenter randomized open-label trial comparing EES with SES in Japan. The trial was powered for evaluating noninferiority of EES relative to SES in terms of target-lesion revascularization. From February and July 2010, 3197 patients were randomly assigned to receive either EES (1597 patients) or SES (1600 patients). At 1 year, the primary efficacy end point of target-lesion revascularization occurred in 65 patients (4.3%) in the EES group and in 76 patients (5.0%) in the SES group, demonstrating noninferiority of EES to SES (P noninferiority Ͻ0.0001, and P superiority ϭ0.34). Cumulative incidence of definite stent thrombosis was low and similar between the 2 groups (0.32% versus 0.38%, Pϭ0.77). An angiographic substudy enrolling 571 patients (EES, 285 patients and SES, 286 patients) demonstrated noninferiority of EES relative to SES regarding the primary angiographic end point of in-segment late loss (0.06Ϯ0.37 mm versus 0.02Ϯ0.46 mm, P noninferiority Ͻ0.0001, and P superiority ϭ0.24) at 278Ϯ63 days after index stent implantation. Conclusions-One-year clinical and angiographic outcome after EES implantation was noninferior to and not different from that after SES implantation in a stable coronary artery disease population with relatively less complex coronary anatomy. One-year clinical outcome after both EES and SES use was excellent with a low rate of target-lesion revascularization and a very low rate of stent thrombosis. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035450.
(EES), a second-generation DES, is a cobalt chromium alloy stent with thin (81 m) strut thickness, which is coated with a thin nonadhesive, durable, biocompatible fluorinated copolymer releasing a reduced dose of everolimus in comparison with the dose used in SES. 4 In a pooled analysis of the 4 randomized controlled trials comparing EES with paclitaxeleluting stent (PES), EES demonstrated consistent clinical benefit over PES in terms of myocardial infarction (MI), ST, and TLR up to 2 years of follow-up. [5] [6] [7] However, a more clinically relevant comparator for EES would be SES, which had been demonstrated to be more effective and safer than PES. 8 Currently, 9-month to 3-year follow-up results of 8 head-to-head randomized trials comparing EES with SES have been published. 9 -16 However, among these trials, only 1 trial 16 was powered for a clinical end point, and there was no trial powered for evaluating TLR, which would be the most relevant end point in evaluating efficacy of DES.
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Therefore, we designed a large-scale randomized trial comparing EES with SES, which was powered to evaluate noninferiority followed by superiority in terms of the efficacy outcome (TLR). The trial was of sufficient magnitude to evaluate the effect of EES relative to SES on TLR in the important subgroup of patients with diabetes mellitus (onlineonly Data Supplement Methods).
Methods

Study Design
Randomized Evaluation of Sirolimus-eluting versus Everolimuseluting stent Trial (RESET) is a prospective multicenter randomized, open-label trial comparing EES with SES in Japan. Patients scheduled for percutaneous coronary intervention (PCI) with the use DES among 100 participating centers (online-only Data Supplement Appendix A) were to be enrolled without any exclusion criteria.
Patients were randomly assigned to undergo PCI with either EES (Xience V) or SES (Cypher Select-plus). Randomization was performed at any time before the attempt of stent implantation and was stratified by center, diabetic status, and participation in the imaging substudies (angiography, intravascular ultrasound, optical coherence tomography, and coronary endothelial function). Patients enrolled in the imaging substudies were not randomly selected, but were selected by the site investigators. The study-group assignments were blinded to the statistician, members of the independent clinical events committee, steering committee, academic research organization (Research Institute for Production Development, Kyoto, Japan), angiographic core laboratory (Cardiocore, Tokyo, Japan), and the sponsor (Abbott Vascular) (onlineonly Data Supplement Appendix B). The steering committee members designed the study in collaboration with the sponsor.
The study protocol was approved by the institutional review board at each participating center. Written informed consent was obtained from all the study patients. The trial was registered with http:// www.clinicaltrials.gov, unique identifier NCT01035450.
Study Procedures
EES was available in diameters of 2.50, 2.75, 3.00, and 3.50 mm with each available in lengths of 8, 12, 15, 23 , and 28 mm. SES was available in diameters of 2.50, 2.75, 3.00, and 3.50 mm, and in lengths of 8, 13, 18, 23 , and 28 mm for stents with a diameter of 2.50 mm, 18 mm, and 23 mm for stents with a diameter of 2.75 mm, and 8, 13, 18, 28, and 33 mm for stents with diameters of 3.00 mm, and 3.50 mm. Use of stents other than the assigned study stent was not allowed unless the delivery of the assigned stent was unsuccessful, in which case crossover to any commercially available coronary stents including the comparator study stent was permitted.
Baseline and follow-up data were collected by the clinical research coordinators belonging to the participating centers, local site management organizations, or the academic research organization. Information on the technical details for the index PCI procedure was recorded during or immediately after the procedure by the dedicated technicians in the cardiac catheterization laboratories. Audits for the baseline data were conducted in 810 patients (25%) by independent clinical research coordinators belonging to the academic research organization. Follow-up information at 1 year was obtained by either a hospital visit or telephone contact with the patient or the referring physician. Patients will continue to be followed annually for 3 years. ECGs and cardiac biomarkers (creatinine kinase MB fraction and troponins) were to be evaluated before and after the index procedure and at the time of suspected ischemic events.
Antithrombotic Therapy
Procedural anticoagulation was achieved with unfractionated heparin according to the local site protocols. The recommended antiplatelet 
Primary and Secondary End Points
The primary efficacy end point was any TLR at 1 year on patient basis, whereas the primary safety end point was a composite of all-cause death or MI at 3 years. TLR was defined as either PCI or coronary artery bypass grafting owing to restenosis or thrombosis of the target lesion that included the proximal and distal edge segments, and the ostium of the side branches, as well. Only those lesions treated at the time of the index randomized PCI procedure were regarded as target lesions, whereas those lesions treated at the time of scheduled staged PCI procedures were not regarded as target lesions. All the angiograms of patients with target-vessel revascularization (TVR) were to be analyzed by the angiographic core laboratory in an attempt to discriminate TLR from non-TLR TVR. Events comprising the primary end points were adjudicated by the independent clinical event committee. Secondary end points included acute device success, duration of the index procedure, clinically driven TLR, TVR, any coronary revascularization, all-cause death, cardiac death, MI, ST, hospitalization for heart failure, stroke, bleeding, a devise-oriented composite, a patient-oriented composite, target-lesion failure, target-vessel failure, and major adverse cardiac events. Definitions of secondary end points are described in the online-only Data Supplement Methods.
Angiographic Substudy and Quantitative Coronary Angiography
Qualitative and quantitative coronary angiography was evaluated at 1 angiographic core laboratory with use of CAAS 5.9 (Pie Medical Imaging). Baseline and postprocedure angiograms were assessed in all patients whose angiograms were available for analysis. The target segment was defined as the entire segment involving the implanted stent and the 5-mm proximal and distal edges adjacent to the stent. A segment treated with multiple overlapping stents was regarded as a single target segment. In addition to the standard angiographic parameters, SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score was also evaluated in patients in whom both left and right coronary angiograms were available for analysis. 17 In patients enrolled in the angiographic substudy, follow-up angiography was to be performed between 240 and 365 days after the index PCI procedure. Follow-up angiography based on local site protocol was allowed in patients who were not participating in the angiographic substudy. Follow-up angiograms were qualitatively and quantitatively analyzed in patients enrolled in the angiographic substudy and in patients with TVR during follow-up. According to the previous studies, angiograms obtained within 14 days after the index PCI procedure were excluded from the angiographic analysis. The primary end point for the angiographic substudy was in-segment late loss. The secondary angiographic end points included in-stent late loss, percentage of diameter stenosis at follow-up, and binary restenosis. Binary restenosis was defined as a diameter stenosis Ն50%.
Statistical Analyses
Categorical variables were compared with the 2 test or Fisher exact test. Continuous variables were expressed as mean valueϮSD or median with interquartile range. Continuous variables were compared by use of the Student t test or the Wilcoxon rank sum test based on their distributions.
The trial was a noninferiority trial, which was powered for noninferiority of EES to SES on the primary efficacy end point at 1 year after the index procedure. With the assumption of 6.9% TLR rate of SES based on the data from the j-Cypher registry, 1 a total of 3000 patients would yield 95% power to detect noninferiority with a noninferiority margin of 3.4%, and 90% power to detect superiority with 2.7 percentage point difference between the stent types at a level of 1-sided type 1 error of 0.025. A total of 3200 patients were to be enrolled considering possible dropout during follow-up.
One-year clinical follow-up was regarded as completed with an allowance of 2 months (at least 10-month follow-up). Clinical outcomes were analyzed according to the intention-to-treat principle. Each end point was assessed by the Kaplan-Meier method and compared by a log-rank test. Effect of treatment was compared by the Cox proportional hazards model and was expressed by a hazard ratio with 95% CI. As a sensitivity analysis, lesion-based analysis of TLR was also conducted in lesions exclusively treated with the study stents. As a subgroup analysis, treatment effect of EES relative to SES was evaluated in several prespecified subgroups.
The angiographic substudy was powered for noninferiority of EES to SES on the primary angiographic end point of in-segment late loss. With the assumption of 0.04Ϯ0.49 mm in-segment late loss of SES based on the data from the Cypher PMS in Japan, 18 a total of 400 patients would yield 97% power to detect noninferiority at a level of 1-sided type 1 error of 0.025 with a noninferiority margin of 0.195 mm used in the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) III trial. 6 A total of 500 patients were to be enrolled in the angiographic substudy considering a possible dropout from the angiographic follow-up.
All statistical analyses were performed by a statistician (T.M.) with the use of JMP 8.0 (SAS Institute Inc, NC) software and SAS 9.2 (SAS Institute Inc, NC). All reported probability values were 2-sided and probability values of Ͻ0.05 were regarded as statistically significant. 
Results
Characteristics of Patients and Revascularization Procedures
From February and July 2010, a total of 3206 patients were enrolled in the trial among 9534 patients who underwent PCI with the use of DES in the participating centers during the enrollment period. Excluding 9 patients who withdrew consent, 3197 patients with 3927 lesions were randomly assigned to receive either EES (1597 patients with 1967 lesions) or SES (1600 patients with 1960 lesions) (Figure 1) .
The study population included large proportions of patients with advanced age, diabetes mellitus, multivessel coronary artery disease, and prior PCI, and significant proportions of patients with heart failure, hemodialysis, left main coronary artery disease, small-vessel disease, chronic total occlusion, and bifurcation lesions, whereas the prevalence of patients with acute myocardial infarction and high SYNTAX score was remarkably low. The 2 groups of patients were well balanced in terms of baseline clinical and lesion characteristics, with the exception of slight but significant excess of patients with previous coronary artery bypass grafting in the SES group. PCI procedures were characterized by predominant single-vessel treatment with a high prevalence of intravascular ultrasound use. Final balloon inflation pressure was significantly lower in the EES group than in the SES group (Table 1) .
Clinical Outcome
EES use in comparison with SES use was associated with a trend toward a higher rate of acute device success and with significantly higher lesion and procedural success rates (Table 1). Periprocedural MI occurred in 29 patients (1.8%) in the EES group and in 40 patients (2.5%) in the SES group (Pϭ0.18).
Days after PCI Cumulative Incidence (%)
During 1-year follow-up, 51 patients were lost to follow-up (32 patients in the EES group, and 19 patients in the SES group, respectively), resulting in complete 1-year follow-up in 3146 patients (98.4%). A large proportion of patients continued dual antiplatelet therapy at 1 year (88.9% in the EES group, and 89.6% in the SES group, Pϭ0.84) (onlineonly Data Supplement Figure I) .
The cumulative incidence of TLR (primary end point) was 4.3% (65 patients with at least 1 event) in the EES group and 5.0% (76 patients with at least 1 event) in the SES group (Table 2 and Figure 2 ). The upper 95% confidence interval (CI); of the difference in the rate of TLR between the EES and SES groups (Ϫ0.7% [95% CI: Ϫ2.1% to 0.8%]) was smaller than the prespecified noninferiority margin of 3.4%, demonstrating noninferiority of EES to SES (P noninferiorityϽ0.0001). However, testing for superiority was not statistically significant (Pϭ0.34). Cumulative incidences of TVR and clinically driven TLR were also not significantly different between the 2 groups (Table 2 and Figure 2) . The angiographic core laboratory evaluated the angiograms at the time of events in 165 TVR events (78%) of 211 TVR events reported.
The sensitivity analysis was conducted in 1889 lesions exclusively treated with EES and 1858 lesions with SES by excluding those lesions with no attempt of stent implantation (59 lesions and 60 lesions), unsuccessful stenting (1 lesion and 5 lesions), crossover to the comparator stent (5 lesions and 16 lesions), and use of stents other than the study stents (13 lesions and 21 lesions). The rate of crossover to the comparator stent among lesions with the attempt of stent implantation was 0.3% in the EES group and 0.8% in the SES group. Cumulative incidence of lesion-based TLR among lesions treated exclusively with the study stents was not different between the EES and SES groups (3.3% and 4.2%; Pϭ0.15) (online-only Data Supplement Figure 2II ). Follow-up angiography was performed in 1853 patients (58%) within the first year after index stent implantation. Follow-up angiography was performed because of chest pain and/or objective evidence of ischemia in 194 patients (clinically driven follow-up angiography), and without chest pain or objective evidence of ischemia in 1659 patients (nonclinically driven follow-up angiography). Cumulative incidence of any TLR within the first year was 27.1% (51 patients with at least 1 event) in patients who underwent clinically driven follow-up angiography, whereas it was 5.6% (90 patients with at least 1 event) in patients who underwent nonclinically driven follow-up angiography. Among 141 first TLR events reported, 90 events (63%) occurred after nonclinically driven follow-up angiography.
For the subgroup analysis, the interaction between the treatment group and the subgroup factor was not significant for any of the subgroup factors. However, cumulative incidence of TLR was numerically lower in the EES group than in the SES group (5.4% and 12.3%) in the subgroup of patients with insulin-treated diabetes mellitus (Figure 3) .
Cumulative incidence of definite ST at 1 year was very low and not significantly different between the EES and SES groups (0.32% and 0.38%; Pϭ0.77). Cumulative incidences of all-cause death, MI, and a composite of all-cause death or MI were not significantly different between the 2 groups (Table 2 and Figure 2 ).
Angiographic Substudy
We enrolled 571 patients (285 patients in the EES group and 286 patients in the SES group) in the angiographic substudy. Baseline patient, lesion, and procedural characteristics were generally similar between the 2 groups of patients with or without enrollment in the angiographic substudy (online-only Data Supplement Tables I and II) . Follow-up angiography was performed in 515 patients (90%) at 278Ϯ63 days after index stent implantation, and follow-up angiograms were available for analysis in the angiographic core laboratory in 482 patients (84%). The primary angiographic end point of in-segment late loss was 0.06Ϯ0.37 mm in the EES group and 0.02Ϯ0.46 mm in the SES group (Table 3 and Figure 4) . The upper 95% CI of the difference in in-segment late loss between the EES and SES groups (0.04 [95% CI: Ϫ0.03 to 0.11] mm) was smaller than the prespecified noninferiority margin of 0.195 mm, demonstrating noninferiority of EES to SES (P noninferiority Ͻ0.0001). There was no significant difference in in-segment late loss between the EES and SES groups for superiority testing (Pϭ0.24). In-stent late loss and rates of binary angiographic restenosis were also not different between the 2 groups (Table 3 and Figure 4 ).
There was a significant interaction between the treatment group and enrollment in the angiographic substudy (P interaction ϭ0.047). The interaction is due to the opposing directions of the treatment effect in the patients enrolled and not enrolled in the angiographic substudy. However, in both subgroups, the cumulative incidence of TLR was not different between the EES and SES groups (6.6% versus 4.0%; Pϭ0.17 with angiographic substudy, and 3.8% versus 5.2%; Pϭ0.08 without angiographic substudy).
Discussion
The main findings of the current study were the following: (1) 1-year clinical and angiographic outcome after EES implantation was noninferior to and not different from that after SES implantation; and (2) 1-year clinical outcome after both EES and SES use was excellent with low rate of TLR and very low rate of definite ST.
Previously reported randomized trials comparing EES with SES, in general, suggested similar efficacy and safety outcomes. 9 -16 However, 2 randomized trials with angiographic primary end points reported lower binary restenosis rates for EES in comparison with SES, 12,15 whereas 1 trial suggested greater in-segment late loss for EES. 14 The current largest randomized trial comparing EES with SES powered for evaluating TLR clearly demonstrated that there were no meaningful differences between the 2 types of limus-eluting stents in terms of TLR at 1 year and angiographic in-segment late loss at 8 months. Very low rates of TLR after both EES and SES use was remarkable considering the relatively high rate of angiographic follow-up. Despite the absence of any exclusion criteria, a relatively small proportion of patients enrolled in the current study had complex anatomic characteristics as evaluated by the SYNTAX score. In the contemporary DES versus DES trials, it might be difficult to demonstrate clinically meaningful differences in efficacy among anatomically less complex patients. However, early restenosis leading to repeated revascularization in anatomically complex patients is still an issue to be addressed in the contemporary PCI using DES, which has been clearly demonstrated in the SYNTAX trial. 19 In the current study, we found an interesting trend toward lower rates of TLR in the EES group in the subgroups of patients with insulin-treated diabetes mellitus or multivessel PCI, who would represent patients with relatively complex anatomy. Furthermore, a recent observational study comparing EES with a historical control group of SES in the real-world consecutive patient series suggested a lower 3-year risk for TVR in the EES group. 20 Considering the low risk of the present population and the limited duration of follow-up, we could not exclude the possibility of superior antirestenostic efficacy of EES. Future head-to-head DES trials might focus more on complex patients such as those in whom coronary artery bypass grafting could be a reasonable alternative.
In a pooled analysis of the 4 trials comparing EES with PES, the TLR rate in the EES group was significantly lower than that in the PES group among nondiabetic patients, but not among diabetic patients, provoking a controversy on the efficacy of EES in diabetic patients. 21 On the other hand, recent pooled analysis of 1183 diabetic patients comparing SES with PES demonstrated reduction of TLR by 35% with SES use. 22 Diabetes mellitus was a large subgroup in the current trial, and TLR outcome was similar between EES and SES, negating concerns on the efficacy of EES in diabetic patients.
In the current study, EES use in comparison with SES use was associated with significantly higher lesion and procedural success rates, suggesting improved deliverability of this newer generation DES. However, newer-generation DES have been developed mainly to overcome the late adverse events related to the first-generation DES, such as very late ST and late TLR. In a recent meta-analysis and an observational study comparing EES with other DES, EES use was associated with marked reduction of ST, particularly very late ST. 23, 24 Indeed, regarding the primary safety end point (a composite of death or MI), which would ultimately be evaluated at 3 years, the Kaplan-Meier curve seemed to be moving in a positive direction for EES. Therefore, despite noninferiority for the primary efficacy end point, it is an open question as to the equivalence of safety. Continued follow-up of the current study patients would provide some insight on whether EES use could have any positive impact on safety.
Study Limitations
Cypher has already left the coronary DES arena. Therefore, the current trial result could not provide guidance regarding selection of coronary DES in clinical practice. However, SES was the most widely used and most extensively studied first-generation DES. Clinical outcome after SES implantation should be regarded as the benchmark for the current and future generations of DES. There are several other limitations in the current study. First, despite the absence of any exclusion criteria, the current study patients actually enrolled seemed not to represent the real-world clinical practice as reported in other all-comers trials. 25 If we put the relatively low-risk profiles of the study patients into perspective, we should admit a limited ability to generalize the findings to the broader population of patients encountered in routine clinical practice. The limited patient and lesion complexity may increase the risk of failing to detect differences in both safety and efficacy between the devices. Second, the actual 1-year rate of TLR in the SES group was lower than expected, leading to a relatively large noninferiority margin. One of the reasons for the low event rate might be that the trial design excluded lesions treated in staged PCI procedures. In the current trial, one fourth of patients underwent staged PCI procedures. A trial design incorporating lesions treated in staged PCI procedures might be preferred in future DES versus DES trials. Third, although the noninferiority margin of 0.195 mm in the angiographic substudy was defined according to that used in the SPIRIT III trial, it seems disproportionate to the actual sizes of in-segment late loss in the current study. If we choose the noninferiority margin of 0.15 mm used in the Randomized Comparison of EverolimusEluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery Disease in Patients with Diabetes Mellitus (ESSENCE-DIABETES) trial, 13 noninferiority of EES could still be declared in the current study (P noninferiority ϭ0.002). If we choose the noninferiority margin of 0.1 mm used in the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) and Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III (LONG-DES-III) trials, 9,14 noninferiority of EES was not met in the current study (P noninferiority ϭ0.1). However, we did not set this 0.1-mm noninferiority margin a priori, and the noninferiority probability value of 0.1 was due to the underpowered comparison (69% power). Fourth, the high prevalence of follow-up angiography based either on the current study protocol or on the local-site protocols certainly inflated the rates of TLR. Finally, the high prevalence of intravascular ultrasound use in the current study was different from the practice patterns outside Japan.
Conclusions
One-year clinical and angiographic outcome after EES implantation was noninferior to and not different from that after SES implantation in a stable coronary artery disease population with relatively less complex coronary anatomy. One-year clinical outcome after both EES and SES use was excellent with a low rate of TLR and a very low rate of definite ST.
